Gsk (GSK) Total Non-Current Liabilities (2009 - 2026)
Gsk (GSK) posted quarterly Total Non-Current Liabilities of -$30.9 billion for Q2 2026, up 5.57% year-over-year from -$29.3 billion in Q2 2025, and little changed quarter-over-quarter from -$31.0 billion in Q1 2026.
Gsk (GSK) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Gsk's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at -$30.9 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 5.57% year-over-year to -$30.9 billion; the TTM figure through Jun 2026 stood at -$30.9 billion (up 5.57% YoY), while the FY2025 annual figure was -$31.3 billion, down 199.35% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at -$30.9 billion, roughly flat from -$31.0 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $32.0 billion in Q4 2022, with the low at -$36.1 billion in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is -$31.6 billion (2023), against an average of -$20.9 billion.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 65.23% in 2022, then plunged 199.82% in 2025.
- Gsk's Total Non-Current Liabilities stood at $32.0 billion in 2022, then slipped by 2.33% to $31.2 billion in 2023, then gained by 1.51% to $31.7 billion in 2024, then sank by 199.82% to -$31.6 billion in 2025, then grew by 2.29% to -$30.9 billion in 2026.
- Business Quant data shows GSK's Total Non-Current Liabilities at -$30.9 billion in Q2 2026, -$31.0 billion in Q1 2026, and -$31.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 32.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.89 Bn |
| Mar 31, 2026 | -31.03 Bn |
| Dec 31, 2025 | -31.62 Bn |
| Sep 30, 2025 | -32.73 Bn |
| Jun 30, 2025 | -32.72 Bn |
| Mar 31, 2025 | -33.02 Bn |
| Dec 31, 2024 | 31.68 Bn |
| Sep 30, 2024 | -30.06 Bn |
| Jun 30, 2024 | -30.23 Bn |
| Mar 31, 2024 | -32.27 Bn |
| Dec 31, 2023 | 31.21 Bn |
| Sep 30, 2023 | -32.75 Bn |
| Jun 30, 2023 | -31.53 Bn |
| Mar 31, 2023 | -32.32 Bn |
| Dec 31, 2022 | 31.95 Bn |
| Sep 30, 2022 | -36.12 Bn |
| Jun 30, 2022 | -35.98 Bn |
| Mar 31, 2022 | -17.64 Bn |
| Dec 31, 2021 | 45.96 Bn |
| Sep 30, 2021 | -47.59 Bn |